Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2014 - 2025)
Zevra Therapeutics (ZVRA) reported Amortization of Deferred Charges of $612000.0 for Q4 2025, up 2.0% on a YoY basis from $600000.0 in Q4 2024, and down 10.66% quarter-over-quarter from $685000.0 in Q3 2025.
Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2014 - 2025) Analysis & Trends
Zevra Therapeutics has reported Amortization of Deferred Charges for 10 years, with the latest figure at $612000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 2.0% year-over-year to $612000.0; the trailing twelve-month figure through Dec 2025 stood at $2.6 million (up 26.81% YoY), and the FY2025 full-year result was $2.6 million, up 26.81% from the prior year.
- Amortization of Deferred Charges for Q4 2025 stood at $612000.0, down from $685000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $779000.0 in Q3 2024, with the low at -$142000.0 in Q4 2021.
- Historically, Amortization of Deferred Charges has averaged $474600.0 across 3 years, with a median of $606000.0 in 2024.
- Annual changes were most pronounced in 2021 — Amortization of Deferred Charges slumped 124.4% — and 2025, when it jumped 177.41%.
- Zevra Therapeutics' Amortization of Deferred Charges stood at -$142000.0 in 2021, then jumped by 522.54% to $600000.0 in 2024, then grew by 2.0% to $612000.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at $612000.0 (Q4 2025), $685000.0 (Q3 2025), and $689000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 612,000.00 |
| Dec 31, 2025 | 612,000.00 |
| Sep 30, 2025 | 685,000.00 |
| Sep 30, 2025 | 685,000.00 |
| Jun 30, 2025 | 689,000.00 |
| Jun 30, 2025 | 689,000.00 |
| Mar 31, 2025 | 663,000.00 |
| Mar 31, 2025 | 663,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 779,000.00 |
| Sep 30, 2024 | 779,000.00 |
| Jun 30, 2024 | 471,000.00 |
| Jun 30, 2024 | 471,000.00 |
| Mar 31, 2024 | 239,000.00 |
| Mar 31, 2024 | 239,000.00 |
| Dec 31, 2021 | -142,000.00 |
| Dec 31, 2021 | -142,000.00 |
| Mar 31, 2021 | 150,000.00 |
| Mar 31, 2021 | 150,000.00 |